A COMPARISON OF THE IMMUNOSUPPRESSIVE EFFECTS OF CYCLOSPORINE A AND CYCLOSPORINE-G INVIVO AND INVITRO

被引:10
作者
RAYAT, G
YATSCOFF, R
SILVERMAN, R
MCKENNA, R
机构
[1] UNIV MANTOBA,DEPT INTERNAL MED,TRANSPLANT IMMUNOL LAB,GG549,HLTH SCI CTR,820 SHERBROOK ST,WINNIPEG R3A 1R9,MB,CANADA
[2] UNIV MANITOBA,DEPT MED MICROBIOL,WINNIPEG R3A 1R9,MB,CANADA
[3] UNIV MANITOBA,DEPT BIOCHEM,WINNIPEG R3A 1R9,MB,CANADA
[4] UNIV MANITOBA,DEPT SURG,WINNIPEG R3A 1R9,MB,CANADA
关键词
D O I
10.1097/00007890-199303000-00029
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In this study we compared the immunosuppressive effects of cyclosporine (Cs) A and G, both in vitro (human and rabbit) and in vivo (rabbit). The 50% inhibitory concentration (IC50) of CsG was up to three times greater than that of CsA for mitogen and alloantigen-induced lymphocyte proliferation (IC50 CsA 1-degrees-MLC = 19+/-4 mug/L vs. IC50 CsG = 60+/-7 mug/L; P<0.01). Kinetic studies in both human and rabbit systems showed that the effectiveness of both drugs was similarly reduced when added at later times after culture initiation. The effects of CsA and CsG in combination on immune responses appeared to be antagonistic at higher and additive at lower drug doses. We also compared the ability of CsA and CsG to displace H-3-CsA from PBMC. The 50% displacement concentration (DC50) for CsG was up to three times greater than that for CsA (DC50 CsA = 1.44+/-2.49X10(-7) M vs. DC50 CsG = 3.9+/-5.4x10(-7) M; P<0.05), suggesting that CsG does not bind as well to PBMC as CsA. In vivo studies using skin allografts confirmed in vitro findings. Both CsA and CsG at 5 and 10 mg/kg/day significantly (P<0.01) prolonged graft survival compared with control animals. However, at these doses and even at 15 mg/kg/day CsG, CsA was more efficacious at prolonging skin graft survival in rabbits (P<0.01), e.g., mean survival time (MST, days) 10 mg/kg/day CsA = >20.5 vs. MST 15 mg/kg/day CsG = 15.0. These results suggest that both in vitro and in vivo in rabbits CsG is less immunosuppressive than CsA.
引用
收藏
页码:623 / 626
页数:4
相关论文
共 18 条
[1]  
BOREL JF, 1991, TRANSPL P, V23, P1867
[2]  
CALNE RY, 1985, LANCET, V1, P1342
[3]   USE OF A MONOCLONAL-ANTIBODY FOR THE THERAPEUTIC MONITORING OF CYCLOSPORINE IN PLASMA AND WHOLE-BLOOD [J].
COPELAND, KR ;
YATSCOFF, RW .
THERAPEUTIC DRUG MONITORING, 1988, 10 (04) :453-458
[4]  
DSOUZA MJ, 1988, DRUG METAB DISPOS, V16, P895
[5]   A COMPARISON OF CYCLOSPORINE-A AND NVA2-CYCLOSOPORINE (CYCLOSPORINE-G) IN A RAT RENAL-ALLOGRAFT MODEL [J].
GRANT, D ;
ZHONG, R ;
STILLER, C ;
WALLACE, C ;
KEOWN, P ;
DUFF, J .
TRANSPLANTATION, 1987, 44 (01) :9-12
[6]  
GRANT D, 1987, TRANSPLANT P, V19, P3494
[7]   CYCLOPHILIN - A SPECIFIC CYTOSOLIC BINDING-PROTEIN FOR CYCLOSPORIN-A [J].
HANDSCHUMACHER, RE ;
HARDING, MW ;
RICE, J ;
DRUGGE, RJ .
SCIENCE, 1984, 226 (4674) :544-547
[8]  
HESS AD, 1986, CRIT REV IMMUNOL, V6, P123
[9]  
HIESTAND PC, 1985, IMMUNOLOGY, V55, P249
[10]  
HIESTAND PC, 1985, TRANSPLANT P, V17, P1362